Loading the session
Loading the session
Loading instrument
$63.60
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +3.7% (SPY −1.6%, XLV +13.5%). 3 months: −19.3% (SPY −0.4%, XLV +15.5%). 1 year: +6.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CYTK, SPY and XLV · as of 4 Nov 2026
18.6M shares were sold short at the 15 Oct 2026 settlement, 15.0% of the 124.4M shares outstanding; covering them would take 8.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $63.60 was 4.6% below its 50-day average ($66.63) and 9.2% below its 200-day average ($70.07). It has closed below the 200-day for 37 sessions, since 15 Sep 2026. The 50-day average crossed below the 200-day on 19 Oct 2026, 12 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $63.60 on 4 Nov 2026: 28.0% below the 52-week high of $88.31 (30 Jun 2026) and 9.6% above the low of $58.05 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
4 Nov 2026 volume of 2.9M shares was 1.6× the average of the 30 sessions before it (1.8M), as the price rose 2.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
September 2, 2025
+40.45%December 27, 2023
+82.54%December 21, 2023
+25.48%